TY - JOUR
AU - Girardi, Paolo
AB - The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do not respond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergic transmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder and one with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125 mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergic mechanisms may be involved in counteracting PMDD symptoms.
TI - Low-Dose Acetazolamide in the Treatment of Premenstrual Dysphoric Disorder: A Case Series
JF - Psychiatry Investigation
DO - 10.4306/pi.2014.11.1.95
DA - 2014-01-01
UR - https://www.deepdyve.com/lp/pubmed-central/low-dose-acetazolamide-in-the-treatment-of-premenstrual-dysphoric-S0CVM00L60
SP - 95
EP - 101
VL - 11
IS - 1
DP - DeepDyve
ER -